Organogenesis Holdings Inc. (NASDAQ: ORGO) Stock Competitors & Peer Comparison
See ORGO's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ORGO and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ORGO | $1.81 | -4.23% | 232.9M | 60.33 | $0.03 | N/A |
| TAK | $17.41 | -0.40% | 55.4B | 12.52 | $1.39 | +3.62% |
| HLN | $9.80 | -1.36% | 43.2B | 18.28 | $0.54 | +1.80% |
| TEVA | $36.74 | +0.71% | 42.8B | 12.54 | $2.93 | N/A |
| VTRS | $16.10 | -1.11% | 18.7B | 6.39 | $2.52 | +2.98% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| ELAN | $22.13 | -2.64% | 11.1B | 20.91 | $1.06 | N/A |
| RDY | $12.39 | -0.48% | 10.3B | 20.30 | $0.61 | +0.67% |
| LNTH | $100.73 | +0.05% | 6.6B | 16.93 | $5.95 | N/A |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
ORGO vs TAK Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, TAK has a market cap of 55.4B. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while TAK trades at $17.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas TAK's P/E ratio is 12.52. In terms of profitability, ORGO's ROE is -0.24%, compared to TAK's ROE of +0.02%. Regarding short-term risk, ORGO is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check TAK's competition here
Haleon plc (NYSE: HLN)
ORGO vs HLN Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, HLN has a market cap of 43.2B. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while HLN trades at $9.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas HLN's P/E ratio is 18.28. In terms of profitability, ORGO's ROE is -0.24%, compared to HLN's ROE of +0.17%. Regarding short-term risk, ORGO is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check HLN's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
ORGO vs TEVA Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, TEVA has a market cap of 42.8B. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while TEVA trades at $36.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas TEVA's P/E ratio is 12.54. In terms of profitability, ORGO's ROE is -0.24%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, ORGO is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check TEVA's competition here
Viatris Inc. (NASDAQ: VTRS)
ORGO vs VTRS Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, VTRS has a market cap of 18.7B. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while VTRS trades at $16.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas VTRS's P/E ratio is 6.39. In terms of profitability, ORGO's ROE is -0.24%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, ORGO is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
ORGO vs ITCI Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas ITCI's P/E ratio is -180.64. In terms of profitability, ORGO's ROE is -0.24%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, ORGO is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check ITCI's competition here
Catalent, Inc. (NYSE: CTLT)
ORGO vs CTLT Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas CTLT's P/E ratio is -27.84. In terms of profitability, ORGO's ROE is -0.24%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, ORGO is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check CTLT's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
ORGO vs ELAN Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, ELAN has a market cap of 11.1B. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while ELAN trades at $22.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas ELAN's P/E ratio is 20.91. In terms of profitability, ORGO's ROE is -0.24%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, ORGO is more volatile compared to ELAN. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check ELAN's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
ORGO vs RDY Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, RDY has a market cap of 10.3B. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while RDY trades at $12.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas RDY's P/E ratio is 20.30. In terms of profitability, ORGO's ROE is -0.24%, compared to RDY's ROE of +0.09%. Regarding short-term risk, ORGO is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check RDY's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
ORGO vs LNTH Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while LNTH trades at $100.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas LNTH's P/E ratio is 16.93. In terms of profitability, ORGO's ROE is -0.24%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, ORGO is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
ORGO vs AMRX Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, AMRX has a market cap of 5.6B. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while AMRX trades at $17.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas AMRX's P/E ratio is 19.62. In terms of profitability, ORGO's ROE is -0.24%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, ORGO is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check AMRX's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
ORGO vs INDV Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, INDV has a market cap of 4.8B. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while INDV trades at $38.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas INDV's P/E ratio is 10.61. In terms of profitability, ORGO's ROE is -0.24%, compared to INDV's ROE of -2.16%. Regarding short-term risk, ORGO is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check INDV's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
ORGO vs SUPN Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, SUPN has a market cap of 2.8B. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while SUPN trades at $47.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas SUPN's P/E ratio is 15.64. In terms of profitability, ORGO's ROE is -0.24%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, ORGO is more volatile compared to SUPN. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check SUPN's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
ORGO vs RGC Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, RGC has a market cap of 2.5B. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while RGC trades at $5.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas RGC's P/E ratio is -356.34. In terms of profitability, ORGO's ROE is -0.24%, compared to RGC's ROE of -2.32%. Regarding short-term risk, ORGO is more volatile compared to RGC. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check RGC's competition here
Bausch Health Companies Inc. (NYSE: BHC)
ORGO vs BHC Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, BHC has a market cap of 2.3B. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while BHC trades at $6.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas BHC's P/E ratio is 1.58. In terms of profitability, ORGO's ROE is -0.24%, compared to BHC's ROE of +0.89%. Regarding short-term risk, ORGO is more volatile compared to BHC. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check BHC's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
ORGO vs DCPH Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas DCPH's P/E ratio is -11.58. In terms of profitability, ORGO's ROE is -0.24%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, ORGO is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check DCPH's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
ORGO vs HCM Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, HCM has a market cap of 2.1B. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while HCM trades at $12.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas HCM's P/E ratio is 4.59. In terms of profitability, ORGO's ROE is -0.24%, compared to HCM's ROE of +0.01%. Regarding short-term risk, ORGO is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check HCM's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
ORGO vs AVDL Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, ORGO's ROE is -0.24%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, ORGO is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check AVDL's competition here
Embecta Corp. (NASDAQ: EMBCV)
ORGO vs EMBCV Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas EMBCV's P/E ratio is N/A. In terms of profitability, ORGO's ROE is -0.24%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, ORGO is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
ORGO vs DVAX Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas DVAX's P/E ratio is -41.89. In terms of profitability, ORGO's ROE is -0.24%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, ORGO is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check DVAX's competition here
Perrigo Company plc (NYSE: PRGO)
ORGO vs PRGO Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, PRGO has a market cap of 1.8B. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while PRGO trades at $12.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas PRGO's P/E ratio is 5.07. In terms of profitability, ORGO's ROE is -0.24%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, ORGO is more volatile compared to PRGO. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check PRGO's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
ORGO vs ANIP Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while ANIP trades at $75.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas ANIP's P/E ratio is 9.14. In terms of profitability, ORGO's ROE is -0.24%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, ORGO is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check ANIP's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
ORGO vs TARO Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas TARO's P/E ratio is 30.05. In terms of profitability, ORGO's ROE is -0.24%, compared to TARO's ROE of +0.03%. Regarding short-term risk, ORGO is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check TARO's competition here
Harrow Health, Inc. (NASDAQ: HROW)
ORGO vs HROW Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, HROW has a market cap of 1.5B. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while HROW trades at $39.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas HROW's P/E ratio is 437.33. In terms of profitability, ORGO's ROE is -0.24%, compared to HROW's ROE of -1.04%. Regarding short-term risk, ORGO is more volatile compared to HROW. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check HROW's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
ORGO vs PAHC Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while PAHC trades at $33.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas PAHC's P/E ratio is 11.54. In terms of profitability, ORGO's ROE is -0.24%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, ORGO is more volatile compared to PAHC. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check PAHC's competition here
Alvotech (NASDAQ: ALVO)
ORGO vs ALVO Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, ALVO has a market cap of 1.4B. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while ALVO trades at $4.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas ALVO's P/E ratio is -11.79. In terms of profitability, ORGO's ROE is -0.24%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, ORGO is more volatile compared to ALVO. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check ALVO's competition here
Cronos Group Inc. (NASDAQ: CRON)
ORGO vs CRON Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while CRON trades at $3.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas CRON's P/E ratio is 30.10. In terms of profitability, ORGO's ROE is -0.24%, compared to CRON's ROE of +0.06%. Regarding short-term risk, ORGO is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check CRON's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
ORGO vs ETON Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, ETON has a market cap of 1.1B. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while ETON trades at $41.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas ETON's P/E ratio is -594.00. In terms of profitability, ORGO's ROE is -0.24%, compared to ETON's ROE of -0.06%. Regarding short-term risk, ORGO is more volatile compared to ETON. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check ETON's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
ORGO vs PCRX Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, PCRX has a market cap of 932.2M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while PCRX trades at $23.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas PCRX's P/E ratio is 9.12. In terms of profitability, ORGO's ROE is -0.24%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, ORGO is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check PCRX's competition here
PetIQ, Inc. (NASDAQ: PETQ)
ORGO vs PETQ Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas PETQ's P/E ratio is 83.73. In terms of profitability, ORGO's ROE is -0.24%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, ORGO is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check PETQ's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
ORGO vs AMPH Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, AMPH has a market cap of 881M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while AMPH trades at $19.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas AMPH's P/E ratio is 6.82. In terms of profitability, ORGO's ROE is -0.24%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, ORGO is more volatile compared to AMPH. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check AMPH's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
ORGO vs COLL Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, COLL has a market cap of 842.6M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while COLL trades at $25.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas COLL's P/E ratio is 3.26. In terms of profitability, ORGO's ROE is -0.24%, compared to COLL's ROE of +0.16%. Regarding short-term risk, ORGO is more volatile compared to COLL. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check COLL's competition here
Evotec SE (NASDAQ: EVO)
ORGO vs EVO Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, EVO has a market cap of 778M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while EVO trades at $2.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas EVO's P/E ratio is -3.09. In terms of profitability, ORGO's ROE is -0.24%, compared to EVO's ROE of -0.24%. Regarding short-term risk, ORGO is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check EVO's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
ORGO vs IRWD Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, IRWD has a market cap of 711.1M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while IRWD trades at $4.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas IRWD's P/E ratio is 5.54. In terms of profitability, ORGO's ROE is -0.24%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, ORGO is more volatile compared to IRWD. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check IRWD's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
ORGO vs BDSI Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas BDSI's P/E ratio is 6.82. In terms of profitability, ORGO's ROE is -0.24%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, ORGO is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check BDSI's competition here
Evolus, Inc. (NASDAQ: EOLS)
ORGO vs EOLS Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, EOLS has a market cap of 534.7M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while EOLS trades at $8.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas EOLS's P/E ratio is -25.71. In terms of profitability, ORGO's ROE is -0.24%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, ORGO is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check EOLS's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
ORGO vs AQST Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, AQST has a market cap of 530.7M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while AQST trades at $4.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas AQST's P/E ratio is -6.93. In terms of profitability, ORGO's ROE is -0.24%, compared to AQST's ROE of +2.44%. Regarding short-term risk, ORGO is more volatile compared to AQST. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check AQST's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
ORGO vs TLRY Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, TLRY has a market cap of 523.4M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while TLRY trades at $4.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas TLRY's P/E ratio is -4.32. In terms of profitability, ORGO's ROE is -0.24%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, ORGO is more volatile compared to TLRY. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check TLRY's competition here
Canopy Growth Corporation (NASDAQ: CGC)
ORGO vs CGC Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, CGC has a market cap of 432.7M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while CGC trades at $1.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas CGC's P/E ratio is -0.62. In terms of profitability, ORGO's ROE is -0.24%, compared to CGC's ROE of -0.33%. Regarding short-term risk, ORGO is more volatile compared to CGC. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check CGC's competition here
Kamada Ltd. (NASDAQ: KMDA)
ORGO vs KMDA Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, KMDA has a market cap of 396.9M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while KMDA trades at $6.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas KMDA's P/E ratio is 19.66. In terms of profitability, ORGO's ROE is -0.24%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, ORGO is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check KMDA's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
ORGO vs TKNO Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, TKNO has a market cap of 396.2M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while TKNO trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas TKNO's P/E ratio is -23.84. In terms of profitability, ORGO's ROE is -0.24%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, ORGO is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check TKNO's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
ORGO vs ALIM Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas ALIM's P/E ratio is 5.28. In terms of profitability, ORGO's ROE is -0.24%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, ORGO is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check ALIM's competition here
Embecta Corp. (NASDAQ: EMBC)
ORGO vs EMBC Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, EMBC has a market cap of 281.8M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while EMBC trades at $4.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas EMBC's P/E ratio is 1.83. In terms of profitability, ORGO's ROE is -0.24%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, ORGO is more volatile compared to EMBC. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check EMBC's competition here
Landec Corporation (NASDAQ: LNDC)
ORGO vs LNDC Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas LNDC's P/E ratio is -4.04. In terms of profitability, ORGO's ROE is -0.24%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, ORGO is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check LNDC's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
ORGO vs ACB Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, ACB has a market cap of 236.6M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while ACB trades at $3.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas ACB's P/E ratio is -7.80. In terms of profitability, ORGO's ROE is -0.24%, compared to ACB's ROE of -0.21%. Regarding short-term risk, ORGO is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check ACB's competition here
Shineco, Inc. (NASDAQ: TYHT)
ORGO vs TYHT Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas TYHT's P/E ratio is -1.61. In terms of profitability, ORGO's ROE is -0.24%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, ORGO is more volatile compared to TYHT. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check TYHT's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
ORGO vs SIGA Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, SIGA has a market cap of 205.8M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while SIGA trades at $2.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas SIGA's P/E ratio is 10.63. In terms of profitability, ORGO's ROE is -0.24%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, ORGO is more volatile compared to SIGA. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check SIGA's competition here
Organigram Global Inc. (NASDAQ: OGI)
ORGO vs OGI Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, OGI has a market cap of 181.6M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while OGI trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas OGI's P/E ratio is -4.96. In terms of profitability, ORGO's ROE is -0.24%, compared to OGI's ROE of -0.07%. Regarding short-term risk, ORGO is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check OGI's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
ORGO vs LFCR Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, LFCR has a market cap of 178.9M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while LFCR trades at $4.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas LFCR's P/E ratio is -4.46. In terms of profitability, ORGO's ROE is -0.24%, compared to LFCR's ROE of -2.51%. Regarding short-term risk, ORGO is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check LFCR's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
ORGO vs REPH Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas REPH's P/E ratio is -8.04. In terms of profitability, ORGO's ROE is -0.24%, compared to REPH's ROE of -0.22%. Regarding short-term risk, ORGO is more volatile compared to REPH. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check REPH's competition here
Journey Medical Corporation (NASDAQ: DERM)
ORGO vs DERM Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, DERM has a market cap of 177M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while DERM trades at $6.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas DERM's P/E ratio is -17.38. In terms of profitability, ORGO's ROE is -0.24%, compared to DERM's ROE of -0.36%. Regarding short-term risk, ORGO is more volatile compared to DERM. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check DERM's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
ORGO vs CRDL Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, CRDL has a market cap of 175.2M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while CRDL trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas CRDL's P/E ratio is -5.41. In terms of profitability, ORGO's ROE is -0.24%, compared to CRDL's ROE of -2.29%. Regarding short-term risk, ORGO is more volatile compared to CRDL. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check CRDL's competition here
Theratechnologies Inc. (NASDAQ: THTX)
ORGO vs THTX Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas THTX's P/E ratio is -28.83. In terms of profitability, ORGO's ROE is -0.24%, compared to THTX's ROE of +0.17%. Regarding short-term risk, ORGO is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
ORGO vs ASRT Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas ASRT's P/E ratio is -7.10. In terms of profitability, ORGO's ROE is -0.24%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, ORGO is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check ASRT's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
ORGO vs CPIX Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, CPIX has a market cap of 119.3M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while CPIX trades at $7.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas CPIX's P/E ratio is -19.90. In terms of profitability, ORGO's ROE is -0.24%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, ORGO is more volatile compared to CPIX. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check CPIX's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
ORGO vs SCTL Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas SCTL's P/E ratio is -7.86. In terms of profitability, ORGO's ROE is -0.24%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, ORGO is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
ORGO vs BGM Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, BGM has a market cap of 111.9M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while BGM trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas BGM's P/E ratio is -1.01. In terms of profitability, ORGO's ROE is -0.24%, compared to BGM's ROE of -0.07%. Regarding short-term risk, ORGO is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check BGM's competition here
Procaps Group S.A. (NASDAQ: PROC)
ORGO vs PROC Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas PROC's P/E ratio is 1.53. In terms of profitability, ORGO's ROE is -0.24%, compared to PROC's ROE of -2.22%. Regarding short-term risk, ORGO is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
ORGO vs OPTN Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas OPTN's P/E ratio is -4.42. In terms of profitability, ORGO's ROE is -0.24%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, ORGO is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
ORGO vs ZOM Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas ZOM's P/E ratio is -1.62. In terms of profitability, ORGO's ROE is -0.24%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, ORGO is more volatile compared to ZOM. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
ORGO vs GRVI Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas GRVI's P/E ratio is 26.05. In terms of profitability, ORGO's ROE is -0.24%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, ORGO is more volatile compared to GRVI. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check GRVI's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
ORGO vs ZYBT Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, ZYBT has a market cap of 73.5M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while ZYBT trades at $1.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas ZYBT's P/E ratio is -7.05. In terms of profitability, ORGO's ROE is -0.24%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, ORGO is more volatile compared to ZYBT. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check ZYBT's competition here
Talphera, Inc. (NASDAQ: TLPH)
ORGO vs TLPH Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, TLPH has a market cap of 72.7M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while TLPH trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas TLPH's P/E ratio is -4.52. In terms of profitability, ORGO's ROE is -0.24%, compared to TLPH's ROE of -0.93%. Regarding short-term risk, ORGO is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check TLPH's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
ORGO vs ZYNE Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, ORGO's ROE is -0.24%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, ORGO is more volatile compared to ZYNE. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
ORGO vs SSIC Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas SSIC's P/E ratio is 11.93. In terms of profitability, ORGO's ROE is -0.24%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, ORGO is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
ORGO vs VLNS Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas VLNS's P/E ratio is -1.03. In terms of profitability, ORGO's ROE is -0.24%, compared to VLNS's ROE of N/A. Regarding short-term risk, ORGO is more volatile compared to VLNS. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
ORGO vs DRRX Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas DRRX's P/E ratio is -4.44. In terms of profitability, ORGO's ROE is -0.24%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, ORGO is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check DRRX's competition here
InterCure Ltd. (NASDAQ: INCR)
ORGO vs INCR Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, INCR has a market cap of 57.1M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while INCR trades at $0.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas INCR's P/E ratio is -2.23. In terms of profitability, ORGO's ROE is -0.24%, compared to INCR's ROE of -0.09%. Regarding short-term risk, ORGO is more volatile compared to INCR. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check INCR's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
ORGO vs JUPW Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas JUPW's P/E ratio is -2.41. In terms of profitability, ORGO's ROE is -0.24%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, ORGO is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check JUPW's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
ORGO vs CPHI Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, CPHI has a market cap of 44.6M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while CPHI trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas CPHI's P/E ratio is -1.72. In terms of profitability, ORGO's ROE is -0.24%, compared to CPHI's ROE of -0.19%. Regarding short-term risk, ORGO is more volatile compared to CPHI. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check CPHI's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
ORGO vs QLI Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas QLI's P/E ratio is -4.92. In terms of profitability, ORGO's ROE is -0.24%, compared to QLI's ROE of -0.16%. Regarding short-term risk, ORGO is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check QLI's competition here
HEXO Corp. (NASDAQ: HEXO)
ORGO vs HEXO Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas HEXO's P/E ratio is -0.26. In terms of profitability, ORGO's ROE is -0.24%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, ORGO is more volatile compared to HEXO. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check HEXO's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
ORGO vs RMTI Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, RMTI has a market cap of 30.8M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while RMTI trades at $7.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas RMTI's P/E ratio is -7.42. In terms of profitability, ORGO's ROE is -0.24%, compared to RMTI's ROE of -0.15%. Regarding short-term risk, ORGO is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check RMTI's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
ORGO vs AYTU Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, AYTU has a market cap of 25.3M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while AYTU trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas AYTU's P/E ratio is -1.23. In terms of profitability, ORGO's ROE is -0.24%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, ORGO is more volatile compared to AYTU. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check AYTU's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
ORGO vs TXMD Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, TXMD has a market cap of 24.1M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while TXMD trades at $2.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas TXMD's P/E ratio is 105.96. In terms of profitability, ORGO's ROE is -0.24%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, ORGO is more volatile compared to TXMD. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check TXMD's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
ORGO vs CYTH Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas CYTH's P/E ratio is -0.80. In terms of profitability, ORGO's ROE is -0.24%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, ORGO is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check CYTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
ORGO vs EVOK Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas EVOK's P/E ratio is -7.97. In terms of profitability, ORGO's ROE is -0.24%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, ORGO is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check EVOK's competition here
Optimi Health Corp. (NASDAQ: OPTH)
ORGO vs OPTH Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, OPTH has a market cap of 15.3M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while OPTH trades at $4.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas OPTH's P/E ratio is -17.38. In terms of profitability, ORGO's ROE is -0.24%, compared to OPTH's ROE of -0.94%. Regarding short-term risk, ORGO is more volatile compared to OPTH. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
ORGO vs ACRX Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas ACRX's P/E ratio is -0.31. In terms of profitability, ORGO's ROE is -0.24%, compared to ACRX's ROE of -0.93%. Regarding short-term risk, ORGO is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check ACRX's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
ORGO vs BFRIW Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, BFRIW has a market cap of 13.3M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while BFRIW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas BFRIW's P/E ratio is -0.02. In terms of profitability, ORGO's ROE is -0.24%, compared to BFRIW's ROE of -4.77%. Regarding short-term risk, ORGO is less volatile compared to BFRIW. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check BFRIW's competition here
Cosmos Health Inc. (NASDAQ: COSM)
ORGO vs COSM Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, COSM has a market cap of 11.7M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while COSM trades at $0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas COSM's P/E ratio is -0.29. In terms of profitability, ORGO's ROE is -0.24%, compared to COSM's ROE of -0.96%. Regarding short-term risk, ORGO is more volatile compared to COSM. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check COSM's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
ORGO vs AGRX Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas AGRX's P/E ratio is -0.89. In terms of profitability, ORGO's ROE is -0.24%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, ORGO is more volatile compared to AGRX. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
ORGO vs NLTX Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas NLTX's P/E ratio is -0.28. In terms of profitability, ORGO's ROE is -0.24%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, ORGO is more volatile compared to NLTX. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
ORGO vs LCI Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas LCI's P/E ratio is -0.04. In terms of profitability, ORGO's ROE is -0.24%, compared to LCI's ROE of +1.66%. Regarding short-term risk, ORGO is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
ORGO vs ADMP Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas ADMP's P/E ratio is -0.08. In terms of profitability, ORGO's ROE is -0.24%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, ORGO is more volatile compared to ADMP. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check ADMP's competition here
cbdMD, Inc. (AMEX: YCBD)
ORGO vs YCBD Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, YCBD has a market cap of 6.3M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while YCBD trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas YCBD's P/E ratio is -1.49. In terms of profitability, ORGO's ROE is -0.24%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, ORGO is more volatile compared to YCBD. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check YCBD's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
ORGO vs GELS Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, GELS has a market cap of 5.2M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while GELS trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas GELS's P/E ratio is -1.14. In terms of profitability, ORGO's ROE is -0.24%, compared to GELS's ROE of -0.25%. Regarding short-term risk, ORGO is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check GELS's competition here
Mallinckrodt plc (AMEX: MNK)
ORGO vs MNK Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas MNK's P/E ratio is -0.44. In terms of profitability, ORGO's ROE is -0.24%, compared to MNK's ROE of -0.36%. Regarding short-term risk, ORGO is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
ORGO vs FLGC Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas FLGC's P/E ratio is -0.19. In terms of profitability, ORGO's ROE is -0.24%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, ORGO is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check FLGC's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
ORGO vs UPC Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, UPC has a market cap of 3.8M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while UPC trades at $6.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas UPC's P/E ratio is -0.75. In terms of profitability, ORGO's ROE is -0.24%, compared to UPC's ROE of -0.03%. Regarding short-term risk, ORGO is more volatile compared to UPC. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check UPC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
ORGO vs SBFM Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, SBFM has a market cap of 2.9M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while SBFM trades at $1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas SBFM's P/E ratio is -0.20. In terms of profitability, ORGO's ROE is -0.24%, compared to SBFM's ROE of -0.26%. Regarding short-term risk, ORGO is more volatile compared to SBFM. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check SBFM's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
ORGO vs PLXP Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas PLXP's P/E ratio is -0.22. In terms of profitability, ORGO's ROE is -0.24%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, ORGO is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check PLXP's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
ORGO vs SHPH Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, SHPH has a market cap of 2.5M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while SHPH trades at $4.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas SHPH's P/E ratio is -0.20. In terms of profitability, ORGO's ROE is -0.24%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, ORGO is more volatile compared to SHPH. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check SHPH's competition here
Athenex, Inc. (NASDAQ: ATNX)
ORGO vs ATNX Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas ATNX's P/E ratio is -0.02. In terms of profitability, ORGO's ROE is -0.24%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, ORGO is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check ATNX's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
ORGO vs SNOA Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, SNOA has a market cap of 2.3M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while SNOA trades at $1.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas SNOA's P/E ratio is -1.16. In terms of profitability, ORGO's ROE is -0.24%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, ORGO is more volatile compared to SNOA. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check SNOA's competition here
Procaps Group, S.A. (NASDAQ: PROCW)
ORGO vs PROCW Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while PROCW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas PROCW's P/E ratio is N/A. In terms of profitability, ORGO's ROE is -0.24%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, ORGO is more volatile compared to PROCW. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check PROCW's competition here
RedHill Biopharma Ltd. (NASDAQ: RDHL)
ORGO vs RDHL Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, RDHL has a market cap of 1.9M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while RDHL trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas RDHL's P/E ratio is 0.12. In terms of profitability, ORGO's ROE is -0.24%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, ORGO is more volatile compared to RDHL. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check RDHL's competition here
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC)
ORGO vs SXTC Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, SXTC has a market cap of 1.8M. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while SXTC trades at $3.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas SXTC's P/E ratio is 1.18. In terms of profitability, ORGO's ROE is -0.24%, compared to SXTC's ROE of -0.31%. Regarding short-term risk, ORGO is more volatile compared to SXTC. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check SXTC's competition here
cbdMD, Inc. (AMEX: YCBD-PA)
ORGO vs YCBD-PA Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, YCBD-PA has a market cap of 928.2K. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while YCBD-PA trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas YCBD-PA's P/E ratio is -2.69. In terms of profitability, ORGO's ROE is -0.24%, compared to YCBD-PA's ROE of -0.34%. Regarding short-term risk, ORGO is less volatile compared to YCBD-PA. This indicates lower risk in terms of short-term price fluctuations for ORGO.Check YCBD-PA's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTHW)
ORGO vs CYTHW Comparison August 2026
Organogenesis Holdings Inc. (NASDAQ: ORGO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORGO stands at 232.9M. In comparison, CYTHW has a market cap of 928K. Regarding current trading prices, ORGO is priced at $1.81 on the NASDAQ, while CYTHW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORGO currently has a P/E ratio of 60.33, whereas CYTHW's P/E ratio is N/A. In terms of profitability, ORGO's ROE is -0.24%, compared to CYTHW's ROE of -7.30%. Regarding short-term risk, ORGO is more volatile compared to CYTHW. This indicates higher risk in terms of short-term price fluctuations for ORGO.Check CYTHW's competition here